TY - JOUR. T1 - Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1. AU - Fralix, Kimberly D.. AU - Ahmed, Mansoor M.. AU - Mattingly, Cynthia. AU - Swiderski, Carol. AU - McGrath, Patrick C.. AU - Venkatasubbarao, Kolaparthi. AU - Kamada, Nanao. AU - Mohiuddin, Mohammed. AU - Strodel, William E.. AU - Freeman, James W.. PY - 2000/5/1. Y1 - 2000/5/1. N2 - BACKGROUND. A highly tumorigenic cell line designated as UK Pan-1 was established in a surgically removed human pancreatic adenocarcinoma and characterized as having many of the genotypic and phenotypic alterations commonly found in pancreatic tumors. METHODS. The cell line was characterized by its morphology, growth rate in monolayer culture and soft agar, tumorigenicity in nude mice, and chromosomal analysis. Furthermore, the status of p53, Ki-ras mutation and transforming growth factor (TGF)-β receptor expression were determined. The characteristics of UK Pan-1 were compared with those of other commonly ...
My husband's pancreatic cancer treatment. Our doctor, David Fogelman, M.D., explained Ken's pancreatic cancer treatment options using chemotherapy.
Abstract Background Pancreatic carcinoma usually is a fatal disease with no cure, mainly due to its invasion and metastasis prior to diagnosis. We analyzed the gene expression profiles of paired primary pancreatic tumors and metastatic lesions from Ela-c-myc transgenic mice in order to identify genes that may be involved in the pancreatic cancer progression. Differentially expressed selected genes were verified by semi-quantitative and quantitative RT-PCR. To further evaluate the relevance of some of the selected differentially expressed genes, we investigated their expression pattern in human pancreatic cancer cell lines with high and low metastatic potentials. Results Data indicate that genes involved in posttranscriptional regulation were a major functional category of upregulated genes in both primary pancreatic tumors (PT) and liver metastatic lesions (LM) compared to normal pancreas (NP). In particular, differential expression for splicing factors, RNA binding/pre-mRNA processing factors and
Pancreatic cancer treatment with whipple procedure (pancreaticoduodenectomy) (costs for program #146009) ✔ University Hospital of the Ludwig-Maximilians-University Munich ✔ Department of General Surgery, Traumatology and Reconstructive Surgery ✔ BookingHealth.com
Pancreatic cancer treatment with whipple procedure (pancreaticoduodenectomy) (costs for program #158863) ✔ University Hospital Bonn ✔ Department of General, Visceral, Thoracic and Vascular Surgery ✔ BookingHealth.com
MedStar Montgomery Medical Center offers a wide array of advanced Pancreatic Cancer treatments for both complex and common Pancreatic Cancer types.
TY - JOUR. T1 - KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. AU - Guo, Xiaozhong. AU - Friess, Helmut. AU - Graber, Hans U.. AU - Kashiwagi, Mikiya. AU - Zimmermann, Arthur. AU - Korc, Murray. AU - Büchler, Markus W.. PY - 1996/11/1. Y1 - 1996/11/1. N2 - KAI1 is a metastasis suppressor gene for prostate cancer that is located on chromosome 11p11.2-13. Using Northern blot analysis and in situ hybridization, we studied expression of KAI1 mRNA in specimens from 14 normal pancreases and 27 primary pancreatic cancers, and then correlated the findings with the clinical and histopathological parameters of the patients. Northern blot analysis showed increased steady-state levels of KAI1 mRNA expression in 24 of 27 (89%) pancreatic cancer samples. In situ hybridization showed enhanced KAI1 mRNA levels in the pancreatic cancer cells in 82% cancer tissues. The stroma surrounding the cancer mass and normal pancreatic tissue adjacent to the cancer ...
28+ Treatment In India - Ivf In Delhi Fertility Treatment In India, Recent Advances In Treatment Of Malaria, Treatment For Coronary Artery Disease In India Expert Cardiac S, Cancer Treatment In India Advantages, Panchakarma Treatment In India Pachakarma Kerala Kerala Tourism A, Pancreatic Cancer Treatment An Effective Remedy To Curepancreatic Cancer Tourism City, Affordable Gums Periodontal Treatment In India, Breast Cancer Treatment In India | Www.velkommen.org
Pancreatic cancer is known to be the deadliest of all common cancers. Despite all efforts in pancreatic cancer treatment, the five-year survival rates at diagnosis over the past 20 years have only increased from 5% to 8%. Assuming that pancreatic cancer is going to become the second most frequent cause of cancer related death in the next 20 years, we are all encouraged to treat patients in clinical trials to gain improvements in this devastating disease. Areas covered: This review will provide a summary of pancreatic cancer treatment over the last 20 years, starting with the pivotal study in 1997 which showed the superiority of gemcitabine over 5-FU in advanced pancreatic cancer and is marked as the beginning of a new era in pancreatic cancer treatment ...
The Hoag-USC team then carefully tailors a personalized Pancreatic Cancer treatment plan to effectively achieve the best possible outcome for the patient.
➤ Pancreatic cancer treatment in clinics of Anyang, ➤ 16 clinics, Addresses, $ Prices for treatments and diagnostics, ☺ 43 reviews, ✎ Make an appointment, ✉ 3,469 patients are sent for treatment
The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasi
1240 The epidermal growth factor receptor (EGFR) is overexpressed in up to 60% of pancreatic cancer specimens. Recently, erlotinib (a small-molecule tyrosine kinase inhibitor, TKI) was approved for pancreatic cancer treatment. There is an association between TKI response in non-small cell lung cancer (NSCLC) and specific activating mutations in the EGFR tyrosine kinase (TK) domain. The applicability of this paradigm in pancreatic cancer was analyzed by evaluating the presence of activating EGFR TK mutations and EGFR pathway activation in a large cohort of pancreatic adenocarcinoma patients. Pancreatic adenocarcinoma is characterized by an exuberant desmoplastic reaction, masking precise analysis of tumor cells. State-of-the-art laser capture microdissection (LCM) allowed us to selectively isolate pancreatic ductal adenocarcinoma cells from their surrounding stromal elements. DNA, protein, and mRNA were extracted from 30 human frozen pancreatic cancer specimens following LCM of tissue sections ...
Occupational exposure to hydrocarbon solvents has been found to be associated with an increased risk of exocrine pancreatic cancer (EPC), the human tumor with the highest prevalence of K-ras mutations. Ras genes are critical DNA targets for chemical carcinogens. We analysed the relationship between past occupational exposure to hydrocarbon solvents and mutations in codon 12 of the K-ras gene in 107 incident cases of EPC. Information on occupational factors and life-style was obtained from personal interviews conducted during hospital stay. Occupational exposure to hydrocarbon solvents (aliphatic, aromatic, chlorinated, benzene, other organic solvents) was examined using two methods: expert assessment and the Finnish job-exposure matrix (Finjem). Exposure among K-ras mutated EPC cases (n = 83) was compared with that of K-ras wild-type EPC cases (n = 24). An association between K-ras mutations and solvent exposure was observed with Finjem but barely so with the expert assessment. Over 7-fold ...
TY - JOUR. T1 - Stable transduction of human pancreatic adenocarcinoma cells, rat fibroblasts, and bone marrow-derived stem cells with recombinant adeno- associated virus containing the rat preproisulin II gene. AU - Bochan, M. R.. AU - Sidner, R. A.. AU - Shah, R.. AU - Cummings, O. W.. AU - Goheen, M.. AU - Jindal, R. M.. PY - 1998/1/1. Y1 - 1998/1/1. UR - http://www.scopus.com/inward/record.url?scp=0031978015&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0031978015&partnerID=8YFLogxK. U2 - 10.1016/S0041-1345(97)01353-5. DO - 10.1016/S0041-1345(97)01353-5. M3 - Article. C2 - 9532125. AN - SCOPUS:0031978015. VL - 30. SP - 453. EP - 454. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 2. ER - ...
INTRODUCTION: Until now, studies examining the relationship between socioeconomic status and pancreatic cancer incidence have been inconclusive.. AIM: To prospectively investigate to what extent pancreatic cancer incidence varies according to educational level within the European Prospective Investigation into Cancer and Nutrition (EPIC) study.. METHODS: In the EPIC study, socioeconomic status at baseline was measured using the highest level of education attained. Hazard ratios by educational level and a summary index, the relative indices of inequality (RII), were estimated using Cox regression models stratified by age, gender, and center and adjusted for known risk factors. In addition, we conducted separate analyses by age, gender and geographical region.. RESULTS: Within the source population of 407, 944 individuals at baseline, 490 first incident primary pancreatic adenocarcinoma cases were identified in 9 European countries. The crude difference in risk of pancreatic cancer according to ...
ROCKVILLE, Md., Jan. 20, 2017 (GLOBE NEWSWIRE) - Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced an update on the safety and efficacy of RX-3117 in an ongoing Phase IIa clinical trial in metastatic pancreatic cancer at the American Society for Clinical Oncology (ASCO) 2017 Gastrointestinal Cancer Symposium in San Francisco California.. "The data on progression free survival in metastatic pancreatic cancer patients treated with RX-3117 is very encouraging with 20% of patients exhibiting progression free survival of greater than 5.6 months (with one patient having progression free survival of 7.2 months). A majority of the patients enrolled in the trial have already failed 3 or more prior cancer therapies. Current options for these patients are usually limited to palliative or best supportive care; there are no drugs approved for metastatic pancreatic cancer ...
MANHATTAN BEACH, Calif., Nov. 9, 2012 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. (Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO). The phase III study included 861 metastatic pancreatic cancer patients from around the world. Full results from the clinical trial will be presented at the American Society of Clinical Oncologys 2013 Gastrointestinal Cancers Symposium being held in January. "Historically, few effective treatment options for pancreatic cancer have existed. We are thrilled to have a new treatment option for patients with advanced pancreatic cancer. We look forward to learning more ...
There has been a long standing interest in the identification of medicinal plants and derived natural products for developing cancer therapeutics. Our study focuses upon pancreatic cancer, due to its high mortality rate, that is attributed in part to the lack of an effective chemotherapeutic agent. Previous reports on the use of medicinal plant extracts either alone or alongside conventional anticancer agents in the treatment of this cancer have shown promising results. This work aims to investigate the therapeutic properties of a library of medicinal plants from Bangladesh. 56 extracts of 44 unique medicinal plants were studied. The extracts were screened for cytotoxicity against the pancreatic adenocarcinoma cell line Panc-1, using a label-free biosensor assay. The top cytotoxic extracts identified in this screen were tested on two additional pancreatic cancer cell lines (Mia-Paca2 and Capan-1) and a fibroblast cell line (Hs68) using an MTT proliferation assay. Finally, one of the most promising
Many versions of the free Acrobat Reader do not allow Save. You must instead save the PDF from the CG&D Online page you downloaded it from. PC users: Right-click on the Download link and choose the option that says something like "Save Link As...". Mac users should hold the mouse button down on the link to get these same options. ...
Evidence of a protective effect of several antioxidants and other nutrients on pancreatic cancer risk is inconsistent. The aim of this study was to investigate the association for prediagnostic plasma levels of carotenoids, vitamin C, retinol and tocopherols with risk of pancreatic cancer in a case-control study nested within the ... read more European Prospective Investigation into Cancer and Nutrition (EPIC). 446 incident exocrine pancreatic cancer cases were matched to 446 controls by age at blood collection, study center, sex, date and time of blood collection, fasting status and hormone use. Plasma carotenoids (- and -carotene, lycopene, -cryptoxanthin, canthaxanthin, zeaxanthin and lutein), - and -tocopherol and retinol were measured by reverse phase high-performance liquid chromatography and plasma vitamin C by a colorimetric assay. Incidence rate ratios (IRRs) with 95% confidence intervals (95%CIs) for pancreatic cancer risk were estimated using a conditional logistic regression ...
TY - JOUR. T1 - A phase i study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. AU - Wang-Gillam, Andrea. AU - Plambeck-Suess, Stacey. AU - Goedegebuure, Peter. AU - Simon, Peter O.. AU - Mitchem, Jonathan B.. AU - Hornick, John R.. AU - Sorscher, Steven. AU - Picus, Joel. AU - Suresh, Rama. AU - Lockhart, Albert. AU - Tan, Benjamin. AU - Hawkins, Williams G.. PY - 2013/6/1. Y1 - 2013/6/1. N2 - Purpose This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients and methods Patients with advanced pancreatic adenocarcinoma were treated with gemcitabine (1,000 mg/m2)(level 1), gemcitabine (1,000 mg/m 2) plus IMP 321 at 0.5 mg (level 2) and 2.0 mg (level 3), respectively. Safety, toxicity, and immunological markers at ...
To address the role of β(1) integrins in pancreatic cancer progression, we stably knocked down β(1) integrin subunit expression in human FG-RFP pancreatic cancer cells using lentiviral-based RNA interference. We then examined the effects of β(1) integrin subunit knockdown on pancreatic cancer cell adhesion, migration and proliferation on tumor microenvironment-specific extracellular matrix proteins in vitro and on tumor progression in vivo using a clinically relevant fluorescent orthotopic mouse model of pancreatic cancer. Knockdown of the β(1) integrin subunit inhibited cell adhesion, migration and proliferation on types I and IV collagen, fibronectin and laminin in vitro. In vivo, knockdown of the β(1) integrin subunit reduced primary tumor growth by 50% and completely inhibited spontaneously occurring metastasis. These observations indicate a critical role for the β(1) integrin subunit in pancreatic cancer progression and metastasis in particular. Our results suggest the β(1) integrin
CCL Dec - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients   A phase III study of Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, demonstrated improvements in median overall survival in post-gemcitabine metastatic pancreatic cancer patients. The study, NAPOLI-1, was the basis of approval by the FDA in this indication, and the results were recently published in The Lancet.
TY - JOUR. T1 - Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. AU - Belli, Carmen. AU - Piemonti, Lorenzo. AU - DIncalci, Maurizio. AU - Zucchetti, Massimo. AU - Porcu, Luca. AU - Cappio, S.. AU - Doglioni, Claudio. AU - Allavena, Paola. AU - Ceraulo, D.. AU - Maggiora, Paola. AU - Dugnani, Erica. AU - Cangi, Mariagiulia. AU - Garassini, Greta. AU - Reni, Michele. PY - 2016/3/1. Y1 - 2016/3/1. N2 - Purpose: No standard salvage chemotherapy has been identified for metastatic pancreatic adenocarcinoma (mPA), and there is an urgent need for active agents against this disease. This phase II trial explored the activity of trabectedin in mPA progressing after gemcitabine-based first-line chemotherapy. Methods: Patients with gemcitabine-resistant disease received trabectedin 1.3 mg/m2 as a 3-h intravenous continuous infusion every 3 weeks until disease progression or unacceptable toxicity or for a maximum of 6 months. The primary endpoint was ...
Acquired 5-Fluorouracil Resistance in Human Pancreatic Carcinoma Cells. A Paradigm for Chemoresistance Mechanisms in Pancreatic Cancer
The role of tuberous sclerosis complex (TSC) in the pathogenesis of pancreatic cancers remains largely unknown. The present study shows that neurogenin 3 directed Cre deletion of Tsc1 gene induces the development of pancreatic acinar carcinoma. By cross-breeding the Neurog3-cre mice with Tsc1(loxp/loxp) mice, we generated the Neurog3-Tsc1-/- transgenic mice in which Tsc1 gene is deleted and mTOR signaling activated in the pancreatic progenitor cells. All Neurog3-Tsc1-/- mice developed notable adenocarcinoma-like lesions in pancreas starting from the age of 100 days old. The tumor lesions are composed of cells with morphological and molecular resemblance to acinar cells. Metastasis of neoplasm to liver and lung was detected in 5% of animals. Inhibition of mTOR signaling by rapamycin significantly attenuated the growth of the neoplasm. Relapse of the neoplasm occurred within 14 days upon cessation of rapamycin treatment. Our studies indicate that activation of mTOR signaling in the pancreatic ...
By blocking production of GM-CSF in pancreatic cancer cells, the researchers found that they were able to disrupt accumulation of myeloid-derived suppressor cells, liberating the tumor-killing immune response. "Our study suggests a therapeutic strategy for harnessing the anti-tumor potential of the immune system," Dr. Bar-Sagi explained. "Our findings should be applicable to a significant proportion of human pancreatic cancer cases, as the vast majority of human pancreatic cancer samples that we tested express the GM-CSF protein prominently," Dr. Bar-Sagi added. The researchers are hopeful that their findings will open new doors in therapeutic research, eventually leading to new drug therapies that block the production or function of the GM-CSF protein to allow anti-tumor immune cells to attack the cancer cells and halt tumor development. Although the study focuses on pancreatic cancer, KRAS mutations are prevalent in a number of other cancers, including colon and lung cancer. "From a research ...
TY - JOUR. T1 - Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. AU - Fujioka, Shuichi. AU - Sclabas, Guido M.. AU - Schmidt, Christian. AU - Niu, Jiangong. AU - Frederick, Wayne A.. AU - Dong, Qiang G.. AU - Abbruzzese, James L.. AU - Evans, Douglas B.. AU - Baker, Cheryl. AU - Chiao, Paul J.. PY - 2003/3/6. Y1 - 2003/3/6. N2 - We have demonstrated that nuclear factor-κB (NF-κB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-κB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF-κB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IκBα (S32, 36A) (IκBαM) that blocks NF-κB activity. In this study, we showed that inhibiting constitutive NF-κB activity ...
Physical exams mainly focus on the abdomen to check for any masses or fluid buildup, which could indicate pancreatic cancer. Pancreatic cancer can also spread to lymph nodes; the lymph nodes will be looked at carefully for swelling during a physical examination.. Imaging tests use x-rays, magnets, sound waves, or radioactive chemicals to produce pictures of the inside of the body. For pancreatic cancer, these will include computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, somatostatin receptor scintigraphy, positron emission tomography (PET) scans, endoscopic ultrasounds, and angiography.. Blood tests for pancreatic cancer are used to make diagnoses and determine a patients treatment options. These tests may include a CA 19-9 test and CEA test.. Biopsies entail taking a sample of a suspected tumor so it can be examined under the microscope. Biopsies for pancreatic cancer are performed as a last resort and entail surgically removing a pancreatic tissue sample and ...
Pancreas Cancer Treatment of Alternative Pancreas Cancer Alternative Neuro Acupuncture Treatment and Pancreas Cancer Herbal Herbs Alternative Medicine Treatment on Pancreas Cancer Treatment Medical Center Pancreas Cancer Remedies
We identified an aberrant accumulation of cholesteryl ester in human pancreatic cancer specimens and cell lines," Li said. "Depletion of cholesterol esterification significantly reduced pancreatic tumor growth and metastasis in mice.". Findings show that drugs like avasimibe, previously developed for treatment of atherosclerosis, reduced the accumulation of cholesteryl ester. The disease usually kills within a few months of diagnosis. It is hoped the potential new treatment might extend life of pancreatic cancer patients for a year, Cheng said.. The accumulation of cholesteryl ester is controlled by an enzyme called ACAT-1, and findings correlated a higher expression of the enzyme with a poor survival rate for patients. The researchers analyzed tissue samples from pancreatic cancer patients and then tested the drug treatment in a type of laboratory mice referred to as an orthotopic mouse model, developed at the IU School of Medicine. Specimens of human pancreatic tissues were obtained from the ...
Pancreatic cancer is associated with low responsiveness to conventional chemotherapies and its incidence nearly equals its death rate. This warrants the development of novel mechanism-based approaches for the management of pancreatic cancer. This study was designed to determine the potential of sanguinarine, a plant alkaloid known to possess strong antimicrobial, anti-inflammatory, and antioxidant activities, against human pancreatic carcinoma cells. Employing human pancreatic carcinoma AsPC-1 and BxPC-3 cells, we specifically evaluated the pro-apoptotic and cell cycle deregulatory effects of sanguinarine and evaluated the involvement of Bcl-2 family proteins and p53 as the mechanism of the biological effects of sanguinarine. Our data demonstrated that sanguinarine (at low concentrations of 0.1-10 ?M; for 24 h) treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) inhibition of viability and growth, (ii) colony formation ability, (iii) induction of apoptosis, and (iv) G0-G1 phase ...
According to the results of a Phase II clinical trial, the addition of the investigational drug EndoTAG™-1 to chemotherapy with Gemzar® (gemcitabine) may improve survival among patients with inoperable pancreatic cancer. These results were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO).. Pancreatic cancer has one of the highest mortality rates of all cancers. It accounts for approximately 2% of all newly diagnosed cancers in the United States each year but 5% of all cancer deaths. Pancreatic cancer is often called a "silent killer" because its symptoms are usually not recognizable until it has advanced and spread outside the pancreas. As a result the majority of pancreatic cancers are not diagnosed until they have reached advanced stages and are considered incurable.. Chemotherapy is a common treatment for advanced pancreatic cancer. However, due to the poor long-term survival achieved with chemotherapy alone, researchers continue to evaluate novel ways to ...
Tumor microenvironment plays a pivotal role in cancer progression; however, little is known regarding how differences in the microenvironment affect characteristics of cancer cells. Here, we investigated the effects of tumor microenvironment on cancer cells by using mouse tumor models. After 3 cycles of inoculation and extraction of human pancreatic cancer cells, including SUIT-2 and Panc-1 cells, from tumors, distinct cancer cell lines were established; 3P cells from the pancreas obtained using the orthotopic tumor model, and 3sc cells from subcutaneous tissue obtained using the subcutaneous tumor model. On cell re-inoculation of these cells, the 3sc cells and, more prominently, the 3P cells, exhibited higher tumorigenic activity than the parental cells. The 3P cells specifically exhibited low E-cadherin expression and high invasiveness, suggesting that they were endowed with the highest malignant characteristics. RNA-sequence analysis demonstrated that distinct signaling pathways were activated in
Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. The pancreas is a gland about 6 inches long that is shaped like a thin pear lying on its side. The wider end of the pancreas is called the head, the middle section is called the body, and the narrow end is called the...
Researchers used a mouse model to replicate pancreatic cancer as it appears in humans. They also studied pancreatic cancer tissue samples and samples of pre-invasive pancreatic lesions. They found ATDC was expressed in a subset of the pre-invasive cells, and played a role in the development of pancreatic cancer stem cells, the small number of cells in a tumor that fuel its growth and spread. They also discovered that ATDC appears to be involved in helping cancer cells change state - a process called "epithelial-to-mesenchymal transition," or EMT, which results in cells being more loosely associated, allowing them to migrate more easily. Therefore, they suggest ATDC encourages a tumors invasiveness and spread in the early course of pancreatic cancer ...
Halozyme Therapeutics has announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer.
Increasing prevalence of pancreatic cancer will push the treatment market from its current level of $1.9 billion to an impressive $2.9 billion by 2021.
NEW YORK (Reuters Health) - Individuals who have multiple close relatives with pancreatic cancer should undergo surveillance for pancreatic cancer, according to updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Individuals who have at least one first-degree relative with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer are judged to be at significant increased risk of developing pancreatic cancer (|5% lifetime), said Dr. Michael Goggins of Johns Hopkins University, in Baltimore, Maryland. The average risk is higher in those with a more extensive family history (such as two or three first-degree relatives with pancreatic cancer), he told Reuters Health by email. Dr. Goggins and a multidisciplinary team of experts convened in 2018 to update the CAPS consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status. A complete
Using Affymetrix exon arrays, we find that human pancreatic CAFs overexpress the Shh receptor Smo. This overexpression was confirmed in vivo because stromal fibroblasts in human primary pancreatic adenocarcinomas overexpress Smo protein relative to fibroblasts in normal pancreas. The Hedgehog pathway has been identified as activated in CAFs in mouse models of pancreatic cancer. Our results implicate overexpression of Smo as a mechanism responsible for the activation of the Hedgehog pathway in human pancreatic CAFs. Although it remains unclear how paracrine Hedgehog signaling of fibroblasts contributes to tumor growth, recent work suggests that targeting Smo in the tumor stroma may be an effective strategy in treating pancreatic cancer. Previous work identified Shh as a mediator of the desmoplastic response in pancreatic cancer and suggested that the stroma may serve as a barrier to delivery of therapeutic compounds (33). Indeed, Olive et al. (34) recently reported that mice treated with the ...
Surgical operation to remove cancer has been considered as only one method of treatment for permanent cure of pancreatic cancer. However, when pancreatic cancer is identified, the percentage of cases with complete removal is from 20 to 30, which is rather low. Moreover, it is considered as a kind of cancer with a less favorable prognosis as the 5-year survival rate after the surgery remains as only 20%. For the past 20 to 30 years, there hasnt been any breakthrough in treatment method for pancreatic cancer and the rates have always remained low.. In August, 2012, it was discovered that when S-1, oral anticancer drug, was administered as supplementary chemotherapy after surgery to pancreatic cancer patients with removable cancer, the death rate of went down by 44% compared with the cases with conventional treatment by gemcitabine. At the SCC, this has been immediately brought to the clinical use since then.. At the Gastrointestinal Cancers Symposium of the ASCO(American Society of Clinical ...
Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ Investigators demonstrated that transcriptional co-activator with PDZ-binding motif (TAZ), which is associated with drug resistance of pancreatic cancer, is a new direct downstream target of miR-455-3p. [Mol Ther Nucleic Acids] Full Article Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers Scientists assayed the toxicity of monomethyl auristatin E and monomethyl auristatin F conjugated to an anti-transferrin receptor aptamer, Waz, and an anti-epidermal growth factor receptor aptamer, E07, on the pancreatic cancer cell lines Panc-1, MIA PaCa-2, and BxPC3. [Mol Ther Nucleic Acids] Full Article Carnitine Palmitoyltransferase 1C Regulates Cancer Cell Senescence through Mitochondria-Associated Metabolic Reprograming The authors showed that carnitine palmitoyltransferase 1C, an enzyme that catalyzes carnitinylation of fatty acids for transport into ...
The findings, recently presented at UEG Week 2016, mean that pancreatic cancer will become the third leading cause of death from cancer in the EU behind lung and colorectal cancer. Pancreatic cancer mortality rates are increasing in many countries across the EU and it is estimated that 91,500 deaths will occur from the disease next year, compared with 91,000 from breast cancer (see Figure 1 below). The research used time-linear prediction models to estimate mortality rates until 2025, when deaths from pancreatic cancer (111,500) across Europe are projected to have increased by almost 50% since 2010 (76,000). All countries included in the study show varying increases in pancreatic cancer mortality rates from 20% to a staggering 131% increase over the 15-year period (see Figure 2 below). "Pancreatic cancer survival rate is lower than any other cancer. Consequently, it is absolutely vital that patients receive a diagnosis as early as possible to allow for surgery, which is currently the only ...
Background: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5-6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. Methods: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year. Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as: 1) clinical/demographic data (age, gender, ECOG PS, number and location of metastatic sites); 2) Laboratory data (Hematocrit, hemoglobin, glucose, LDH, renal and liver function and CA19-9); 3) Pathologic data (margins, nodal status and grade); 4) Outcomes data (OS, Time to Treatment Failure (TTF), and 2 year-OS). The lowest CA19-9 levels during treatment with gemcitabine were also recorded. We performed a univariate analysis with OS as the ...
The development of methods to accurately detect early pancreatic cancer and to better differentiate benign from malignant disease could greatly improve the outcomes for pancreatic cancer patients. It is known that malignant transformation of epithelial cells of the pancreas results in alterations in the carbohydrate chains of certain proteins secreted or released by these cells. Glycosylated proteins form the basis for current biomarkers for detecting pancreatic cancer and other adenocarcinomas, and refinement of these tests are predicted to enable detection of early pancreatic cancer. Our preliminary data has shown that a novel antibody-microarray technology allows the efficient detection of glycans on distinct proteins and the identification of specific glycan structures associated with pancreatic cancer. The method uses antibody microarrays to capture specific proteins from serum samples, followed by the incubation of a glycan-binding protein (such as a lectin) to quantify specific glycans on ...
At this time, cancer of the pancreas can be cured only when its found at an early stage (before it has spread) and only if surgery can completely remove the tumor. For people who cant have surgery, other treatments may be able to help them live longer and feel better.. You may have a team of specialists to help plan your treatment. Specialists who treat cancer of the pancreas include surgeons, medical oncologists, radiation oncologists, and gastroenterologists.. Your health care team can describe your treatment choices, the expected results of each, and the possible side effects. Because cancer treatments often damage healthy cells and tissues, side effects are common. These side effects depend on many factors, including the type and extent of treatment. Side effects may not be the same for each person, and they may even change from one treatment session to the next. Before treatment starts, ask your health care team about possible side effects and how treatment may change your normal ...
Most patients with pancreatic cancer are either unresectable at diagnosis or will suffer from a relapse after initial surgery, resulting in a 5-year OS of 6% (11). The median OS of patients with advanced or metastatic pancreatic cancer is 6 months with most chemotherapeutic options (4). Treatment with FOLFIRINOX has offered a new option for patients with advanced pancreatic cancer and a good performance status (8). However, it was reported that a considerable percentage of patients, up to 50%, treated with FOLFIRINOX experienced grade 3 and 4 toxicities (7,8). Understanding the features that determine response or resistance to this chemotherapy regimen could permit the selection of the most suitable patients for treatment with FOLFIRINOX. Thus, in our study, we evaluated clinical and histological markers and their associations with response to FOLFIRINOX.. The objective response rate, defined as the percentage of patients with CR and PR, was slightly higher (55.1%) in our overall study ...
At this time, cancer of the pancreas can be cured only when its found at an early stage (before it has spread) and only if surgery can completely remove the tumor. For people who cant have surgery, other treatments may be able to help them live longer and feel better.. You may have a team of specialists to help plan your treatment. Specialists who treat cancer of the pancreas include surgeons, medical oncologists, radiation oncologists, and gastroenterologists.. Your health care team can describe your treatment choices, the expected results of each, and the possible side effects. Because cancer treatments often damage healthy cells and tissues, side effects are common. These side effects depend on many factors, including the type and extent of treatment. Side effects may not be the same for each person, and they may even change from one treatment session to the next. Before treatment starts, ask your health care team about possible side effects and how treatment may change your normal ...
SCOTTSDALE, Ariz. - A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time at the TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.. ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, said Dr. Daniel Von Hoff, a principal investigator in the Phase I clinical trial and Physician-In-Chief at the Translational Genomics Research Institute (TGen).. More than 36,000 Americans are expected to die in 2010 from pancreatic cancer, making it the fourth leading cause of cancer death in the United States. Most patients with advanced pancreatic cancer die within one year of diagnosis.. "ASG-5ME is intended for pancreatic cancer patients who do not have a good prognosis with currently available therapies. We are very pleased to be able to offer this exciting agent in a clinical trial for patients with advanced pancreatic cancer," said Dr. Von Hoff, Chief Scientific Officer at ...